Dosage protocol · Metabolic & Weight Loss
Mazdutide 5 mg
Typical weekly range: 2.5–6 mg once weekly with gradual titration.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration (standard protocol).
- Typical weekly range: 2.5–6 mg once weekly with gradual titration.
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.[7]
BAC water3.0mL
Concentration1.67mg/mL
Reconstitution
Mazdutide dosage chart
Mazdutide dosage chart · 1
| Week | Week | Draw |
|---|---|---|
| Weeks 1–4 | 2.5 mg (2,500 mcg) | 150 units1.50 mL |
| Weeks 5–8+ | 5 mg (5,000 mcg) | 300 units3.00 mL |
Mazdutide dosage chart · 2
| Week | Week | Draw | Notes |
|---|---|---|---|
| Weeks 1–4 | 5 mg (5,000 mcg) | 200 units2.00 mL | 1 vial |
| Weeks 5–8 | 7.5 mg (7,500 mcg) | 300 units3.00 mL | 1.5 vials |
| Weeks 9–12+ | 10 mg (10,000 mcg) | 400 units4.00 mL | 2 vials; split into 2 injections |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
Mazdutide (research code IBI362) is a synthetic peptide drug candidate designed to activate two hormone receptors at once: the GLP-1 receptor and the glucagon receptor. It belongs to the same broad incretin-drug family as approved medicines like semaglutide and tirzepatide, but its specific dual-receptor combination is unique to its own clinical program.
Mazdutide is being developed mainly for obesity, overweight, and type 2 diabetes, with clinical trials concentrated in China, where its development is furthest along.[1] It is not a finished, approved medicine — it remains an investigational compound moving through clinical-trial phases.
Benefits & side effects
Mazdutide has advanced through randomized, placebo-controlled Phase 2 and Phase 3 trials, mostly in Chinese adults, evaluating body-weight change in people with obesity or overweight and glycemic control in type 2 diabetes, including a head-to-head comparison against the approved GLP-1 drug dulaglutide.[9] Phase 3 obesity trials have reported weight loss at multiple weekly doses (in the 4 mg to 10 mg range) compared with placebo.[8]
This is genuine clinical-trial evidence, but it is still concentrated in one population, over a relatively short follow-up, and has not been replicated at the scale or geographic breadth of the evidence behind semaglutide or tirzepatide. Preclinical animal and mechanistic studies support the liver-fat and energy-expenditure rationale but do not establish outcomes in people.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.
1
Reconstitution
mg
mL
Concentration—
Per unit (0.01 mL)—
Per 10 units (0.1 mL)—
2
Your dose
Doses per vial—
Vial lasts—
Draw to
— units
=
—
Other vial sizes
